Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 5.193
Filtrar
1.
Medicine (Baltimore) ; 102(2): e32493, 2023 Jan 13.
Artigo em Inglês | MEDLINE | ID: mdl-36637961

RESUMO

INTRODUCTION: Splenic malignancies are mostly lymphocytic tumors and splenic metastases are rarer.[1] According to reports, the most common source of splenic metastases include melanoma, tumors of the breast, lung, ovary, colon, stomach, and pancreas.[2,3]. PATIENT CONCERNS: This paper reports a 41-year-old male patient who underwent a successful resection of low rectal cancer in our hospital 5 years ago. DIAGNOSIS: Three months ago, computed tomography scan revealed a tumor in the spleen, considered as an isolated metastasis. INTERVENTIONS: The patient underwent splenectomy and postoperative pathological examination confirmed metastatic adenocarcinoma. OUTCOMES: The patient was followed up for 3 months after surgery, there was no abdominal metastasis or recurrence. CONCLUSION: The splenic metastasis from rectal carcinoma 5 years after surgery is rare. If it is a solitary splenic metastasis, splenectomy can effectively improve the prognosis of patients. We review the literature and report this case.


Assuntos
Adenocarcinoma , Melanoma , Neoplasias Retais , Neoplasias Esplênicas , Masculino , Feminino , Humanos , Adulto , Neoplasias Esplênicas/patologia , Adenocarcinoma/patologia , Tomografia Computadorizada por Raios X , Esplenectomia/métodos , Neoplasias Retais/cirurgia
2.
Medicine (Baltimore) ; 101(47): e31642, 2022 Nov 25.
Artigo em Inglês | MEDLINE | ID: mdl-36451413

RESUMO

INTRODUCTION: Undifferentiated pleomorphic sarcoma (UPS) primarily occurs in the soft tissues of the extremities, trunk, and retroperitoneum. As the primary UPS of the spleen (splenic UPS) is extremely rare, to the best of our knowledge, only 19 cases have been reported in English literature. No cases of long-term survival without a local or distant recurrence have been reported. PATIENT CONCERNS: We report the case of a 37-year-old man who was referred to our hospital for a splenic tumor. He had no past medical or relevant familial history. On abdominal computed tomography (CT), a low attenuation solid mass and cystic component with mural calcifications were present at the lower pole of his spleen. The fluorodeoxyglucose-positron emission tomography (CT) indicated it as malignant tumor of the spleen. DIAGNOSES: The patient's provisional diagnosis was deduced to be angiosarcoma, which was the most common malignant tumor of the spleen. INTERVENTIONS: An elective laparoscopic splenectomy was performed, and the histology of the tumor was consistent with UPS (pT1, pN0, cM0, and AJCC8th). No adjuvant therapy was administered. OUTCOMES: Ten years have passed since the patient's splenectomy, and he continues to do well, without evidence of local or distant recurrence. LESSONS: To the best of our knowledge, this is the first case of long-term recurrence-free survival after surgical management of a splenic UPS. It is probable that radical splenectomy during the disease played the most important role in the patient's long-term survival. Understanding the characteristic findings of a splenic UPS in an abdominal CT may help to diagnose properly.


Assuntos
Histiocitoma Fibroso Maligno , Neoplasias Esplênicas , Masculino , Humanos , Adulto , Intervalo Livre de Doença , Neoplasias Esplênicas/diagnóstico , Neoplasias Esplênicas/cirurgia , Intervalo Livre de Progressão
3.
Arkh Patol ; 84(6): 52-55, 2022.
Artigo em Russo | MEDLINE | ID: mdl-36469718

RESUMO

The article presents a rare case of bone marrow metastasis of the spleen angiosarcoma. The observation is of particular interest due to the fact that secondary bone marrow damage in angiosarcoma in the vast majority of cases is due by primary tumor growth in the spleen. Clinically, such cases may resemble the course of blood diseases with hematological disorders and splenomegaly. Patients come into the field of view of a hematologist, and the final diagnosis is unexpected to the attending physician. Detection of angiosarcoma growth in a bone marrow trephine biopsy during morphological examination can be a rare finding for a pathologist. In this regard, the presented case is of interest not only for pathologists, but also for doctors of clinical specialties.


Assuntos
Neoplasias da Medula Óssea , Hemangiossarcoma , Neoplasias Esplênicas , Humanos , Hemangiossarcoma/diagnóstico , Hemangiossarcoma/complicações , Hemangiossarcoma/patologia , Medula Óssea/patologia , Neoplasias Esplênicas/diagnóstico , Neoplasias Esplênicas/complicações , Neoplasias Esplênicas/patologia
4.
Anticancer Res ; 42(12): 5937-5944, 2022 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-36456133

RESUMO

BACKGROUND/AIM: Total gastrectomy with splenectomy (TGS) is routinely performed in patients with type 4 or large type 3 gastric cancer (GC), which sometimes metastasize to splenic hilar lymph nodes (LNs). However, the indication for and significance of TGS remain controversial. This multicenter retrospective study aimed to evaluate the oncological feasibility of laparoscopic TGS (LTGS) in patients with advanced proximal GC. PATIENTS AND METHODS: We retrospectively studied patients with type 4 or large type 3 GC who underwent LTGS at three Institutes between January 2010 and December 2018. RESULTS: We identified 26 consecutive eligible patients for analysis. Large type 3/type 4 were observed in 10 (38.5%)/16 (61.5%) cases. Involvement of the greater curvature was observed in 19 cases (73.1%), and GC spread to the whole stomach was observed in 12 cases (46.2%). R0 resection was achieved in 23 cases (88.5%). The median number of retrieved splenic hilar LNs was 4.0 (1-15), and the number of cases with splenic hilar LN metastasis was 3 (11.5%). Postoperative grade II intra-abdominal abscess was observed in 1 case (3.8%), and pancreatic fistula was not observed in any patient. Recurrence was observed in 18 cases (69.2%), of which 16 (88.9%) presented peritoneal recurrence. The median overall survival (OS) was 40.6 months, and the 5-year OS rate was 30.3%. The 5-year survival rate of patients with splenic hilar LN metastasis was 33.3% and the therapeutic value of splenectomy was 3.83. CONCLUSION: LTGS was performed safely, but the oncological benefit of the procedure for type 4 or large type 3 GC was very limited.


Assuntos
Laparoscopia , Segunda Neoplasia Primária , Neoplasias Esplênicas , Neoplasias Gástricas , Humanos , Neoplasias Gástricas/cirurgia , Esplenectomia , Estudos Retrospectivos , Gastrectomia/efeitos adversos , Complicações Pós-Operatórias , Laparoscopia/efeitos adversos
5.
PLoS One ; 17(12): e0279594, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36548371

RESUMO

Canine splenic hemangiosarcoma (HSA) is an aggressive tumor with a short overall survival time (OST) despite treatment with splenectomy and adjuvant doxorubicin. Modulation of the immune system has been shown to be effective for a variety of human tumors, and may be effective for canine tumors, including HSA. Immunocidin® is a non-specific immunotherapy based on a mycobacterial cell wall fraction. Preliminary work suggests Immunocidin® is safe to give intravenously (IV) in tumor-bearing dogs. This work aimed to evaluate the safety of doxorubicin and Immunocidin® combination in dogs with naturally occurring splenic HSA. A secondary aim of this study was to collect preliminary efficacy data to support a subsequent comprehensive, prospective clinical trial in canine patients with HSA, if the combination of doxorubicin and Immunocidin® was found to be safe. Eighteen dogs with stage II-III splenic HSA were recruited to receive 5 doses of sequential IV doxorubicin and Immunocidin® at two-week intervals following splenectomy. Adverse events (AEs) were graded according to the Veterinary Cooperative Oncology Group v1.1 (VCOG) scheme. Overall survival time was calculated from the date of splenectomy to date of death or loss to follow-up. AEs during administration were infrequent, the most common being hypertension. One patient developed limb and facial twitching and was removed from the study. After infusion, common AEs included lethargy, hyporexia, and diarrhea. One patient developed VCOG grade 5 diarrhea, thrombocytopenia, and anemia. Modifications in the treatment regimen were made to prevent these signs in subsequent patients. The median OST in dogs treated with the combination therapy was estimated at 147 days (range: 39-668 days). Although generally safe, the combination of doxorubicin and Immunocidin® appeared to cause more gastrointestinal effects than doxorubicin alone, and no apparent improvement in OST was noted in this population of dogs.


Assuntos
Doenças do Cão , Hemangiossarcoma , Neoplasias Esplênicas , Animais , Cães , Humanos , Doenças do Cão/tratamento farmacológico , Doxorrubicina/efeitos adversos , Hemangiossarcoma/tratamento farmacológico , Hemangiossarcoma/veterinária , Imunoterapia , Estudos Prospectivos , Neoplasias Esplênicas/veterinária
6.
Rinsho Ketsueki ; 63(10): 1379-1385, 2022.
Artigo em Japonês | MEDLINE | ID: mdl-36351643

RESUMO

There is currently no evidence that a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine might be associated with the development of autoimmune hemolytic anemia or disease progression in patients with mature B-cell neoplasm. Our patient was a 71-year-old man with indolent mature B-cell neoplasm who had been monitored for many years without treatment. After receiving the second dose of the BNT162b2 mRNA COVID-19 vaccine, he developed severe warm autoimmune hemolytic anemia. Although steroid therapy improved his anemia, he continued to develop IgM-monoclonal gammopathy, renal insufficiency, and splenomegaly. He was diagnosed with splenic marginal zone lymphoma after undergoing splenectomy. The splenectomy improved the patient's symptoms. We assessed his SARS-CoV-2 specific antibody response, but the patient's serologic response to the vaccine was impaired. In patients with mature B-cell neoplasm, a non-specific immune response after vaccination might be associated with paraneoplastic syndromes.


Assuntos
Anemia Hemolítica Autoimune , Vacinas contra COVID-19 , COVID-19 , Leucemia Linfocítica Crônica de Células B , Linfoma de Células B , Paraproteinemias , Neoplasias Esplênicas , Idoso , Humanos , Masculino , Anemia Hemolítica Autoimune/etiologia , Anemia Hemolítica Autoimune/complicações , Vacina BNT162 , COVID-19/complicações , Vacinas contra COVID-19/efeitos adversos , Imunoglobulina M , Leucemia Linfocítica Crônica de Células B/complicações , Linfoma de Células B/tratamento farmacológico , Paraproteinemias/complicações , SARS-CoV-2 , Neoplasias Esplênicas/complicações
8.
Am J Vet Res ; 83(12)2022 Nov 07.
Artigo em Inglês | MEDLINE | ID: mdl-36327166

RESUMO

OBJECTIVE: To determine luteinizing hormone receptor (LHR) expression and response to LHR activation in isolated canine splenic hemangiosarcoma cell lines in vitro. SAMPLES: In vitro cultures of commercially available canine splenic hemangiosarcoma cell lines (EFS, GRACE-HSA, and DAL-4). PROCEDURES: The percentage of each cell line expressing LHR was determined by immunocytochemistry. Cells were then treated with increasing doses (7.5 ng/mL, 75 ng/mL) of recombinant canine luteinizing hormone (cLH) for 48 hours and evaluated using a cell proliferation assay. RESULTS: The percentage of cells expressing LHR was 17.2 ± 4.5%, 11.8 ± 3.1%, and 6.9 ± 2.5% in EFS, GRACE-HSA, and DAL-4, respectively. There was significant increase in cell count in the DAL-4 and EFS cell lines following a 48-hour incubation at the highest cLH concentration (P = .028 and P = .019, respectively). There was not a significant increase in cell count in the GRACE-HSA cell line at either cLH concentration. CLINICAL RELEVANCE: Activation of LHR results in cell proliferation in some canine splenic hemangiosarcoma cell lines. These results may explain why spayed and castrated dogs with high circulating LH concentrations may develop hemangiosarcoma more frequently than intact dogs.


Assuntos
Doenças do Cão , Hemangiossarcoma , Neoplasias Esplênicas , Cães , Animais , Hemangiossarcoma/veterinária , Hemangiossarcoma/tratamento farmacológico , Receptores do LH/genética , Doenças do Cão/tratamento farmacológico , Neoplasias Esplênicas/veterinária , Linhagem Celular Tumoral
9.
Gan To Kagaku Ryoho ; 49(10): 1163-1165, 2022 Oct.
Artigo em Japonês | MEDLINE | ID: mdl-36281620

RESUMO

Recurrent gastric cancer(GC)with splenic metastasis showed poor prognosis, and its treatment strategy remains unclear. Recently, studies identified the considerable prognostic effect of metastasectomy in GC following intensive chemotherapy. Here, we successfully treated a patient with Epstein-Barr virus-positive esophagogastric junctional cancer with splenic metastasis who underwent metastasectomy and obtained pathological complete response following immune checkpoint therapy and had long-term survival. We reviewed the literature to discuss the clinical significance of our treatment strategy.


Assuntos
Infecções por Vírus Epstein-Barr , Metastasectomia , Segunda Neoplasia Primária , Neoplasias Esplênicas , Neoplasias Gástricas , Humanos , Herpesvirus Humano 4 , Infecções por Vírus Epstein-Barr/complicações , Neoplasias Esplênicas/cirurgia , Recidiva Local de Neoplasia , Prognóstico , Neoplasias Gástricas/tratamento farmacológico , Neoplasias Gástricas/cirurgia
10.
Bull Exp Biol Med ; 173(5): 575-582, 2022 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-36210412

RESUMO

The review analyses the frequency of malignant tumors metastasizing to the spleen. The facts are presented of a higher frequency of metastasis to the spleen in the presence of multiple metastases to other organs and the extreme rarity of isolated metastases to the spleen. Despite the rarity of spleen metastases, their frequency varies depending on the nosological form of the malignancy. The data about clinical manifestations of spleen metastases and positive effects of splenectomy in these cases are presented. The hypotheses explaining the rarity of metastases to the spleen are analyzed. Emphasis is placed on the multiple immune functions of the spleen, including the development of immunogenesis and tolerance, and the possible role of these processes in inhibiting the development of spleen metastases. However, to date, there is no complete understanding of the mechanisms of spleen metastasis inhibition. The spleen is an area where antimetastatic microenvironment is naturally formed. Understanding of the mechanisms inhibiting the development of metastases in the spleen and underlying the failure of this function in cases where metastases do occur could arm oncologists with a new strategy to prevent metastasis to any organ. Targeted research in this field is required.


Assuntos
Neoplasias Esplênicas , Humanos , Esplenectomia , Neoplasias Esplênicas/secundário , Microambiente Tumoral
11.
Pan Afr Med J ; 42: 131, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36060838

RESUMO

Neuroendocrine carcinoma (NEC) in the stomach represents a rare and rapidly growing type of gastric tumors. They are considered a distinct entity of neuroendocrine tumors characterized by an aggressive behavior and high metastases rate. On the other hand, spleen metastases of neuroendocrine tumors are extremely rare. We report the first case of spleen metastases of gastric neuroendocrine carcinoma. The patient was a 54-year-old male who presented with a 10-month history of epigastralgia. Upper gastro-intestinal endoscopy revealed a 5 cm ulcerative lesion located in the greater gastric curvature. Biopsies with immunohistochemical staining revealed gastric neuroendocrine carcinoma. Abdominal computed tomography showed thickening of the stomach with two large solid spleen lesions. Abdominal Magnetic Resonance Imaging and 18-fluorodexyglucose positron-emission tomography revealed peritoneal carcinosis and splenic metastases with splenic vein invasion. Clinicians should keep in mind that splenic metastases can arise from gastric neuroendocrine tumors (NETs).


Assuntos
Carcinoma Neuroendócrino , Tumores Neuroendócrinos , Neoplasias Esplênicas , Neoplasias Gástricas , Carcinoma Neuroendócrino/diagnóstico , Carcinoma Neuroendócrino/patologia , Humanos , Masculino , Pessoa de Meia-Idade , Tumores Neuroendócrinos/diagnóstico , Tumores Neuroendócrinos/patologia , Neoplasias Esplênicas/diagnóstico , Neoplasias Gástricas/diagnóstico , Neoplasias Gástricas/patologia
12.
J Cancer Res Ther ; 18(4): 1093-1097, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36149166

RESUMO

Background: Hepatosplenic T-cell lymphoma (HSTCL) is a rare fatal T-cell neoplasm with unique clinical and laboratory features. There is, however, significant morphological and immunophenotypic heterogeneity which may lead to diagnostic dilemma. Aims and Objectives: The study was aimed to study the prevalence and clinic-pathological spectrum of this rare variant of T cell lymphoma in the Indian subcontinent. Material and Methods: A retrospective analysis of all consecutive cases of HSTCL diagnosed over a period of 6 years was carried out. The clinical and laboratory parameters of all these patient were reviewed and analysed. Results: A total of 12 cases of HSTCL were diagnosed during this period which accounted for 1.76% of all non-Hodgkin's lymphomas (NHLs) and 9.1% of all T-cell NHLs. The median (range) age of presentation was 23 (16-30) years.Leukocytosis, peripheral blood (PB) involvement, and a blastic morphology were noted in 41%, 67%, and 58% of the cases, respectively. FCI proved these cells to have a mature, dual-negative (CD4-/CD8-) T-cell phenotype with a gamma-delta T-cell receptor restriction. Frequent loss of CD5 expression (84%) was also noted. These patients invariably had a fatal outcome and majority died within a year of diagnosis. Conclusion: The incidence of leukocytosis and a blastoid morphology is quite frequent in HSTCL. Hence, a differential diagnosis of HSTCL should always be considered in young patients presenting with splenomegaly and exhibiting atypical lymphoid/blastoid cells in the PB or a marrow. An FCI can readily diagnose and differentiate them from an acute lymphoblastic leukemia/lymphoma.


Assuntos
Neoplasias Hepáticas , Linfoma de Células T , Neoplasias Esplênicas , Citometria de Fluxo , Humanos , Leucocitose , Neoplasias Hepáticas/diagnóstico , Neoplasias Hepáticas/epidemiologia , Neoplasias Hepáticas/genética , Linfoma de Células T/diagnóstico , Linfoma de Células T/epidemiologia , Receptores de Antígenos de Linfócitos T gama-delta/análise , Receptores de Antígenos de Linfócitos T gama-delta/genética , Estudos Retrospectivos , Neoplasias Esplênicas/diagnóstico , Neoplasias Esplênicas/epidemiologia
13.
Med Oncol ; 39(12): 224, 2022 Sep 29.
Artigo em Inglês | MEDLINE | ID: mdl-36175723

RESUMO

Gastric cancer represents one of the leading causes of cancer-related death worldwide. Even if the last decade has witnessed an improvement in surgical and systemic treatments, with an increase of overall life expectancy, survival rates still remain unsatisfactory, especially for patients with metastatic disease. Systemic therapies represent the gold standard in the management of stage IV gastric cancer. In this scenario, the availability of effective second and third lines has represented for a long time the only hope to offer an overall survival improvement to these patients. Recently, the advent of immune checkpoint inhibitors has involved also gastric cancer with encouraging efficacy data in the metastatic setting, becoming integral part of the management of selected patients.


Assuntos
Neoplasias Esplênicas , Neoplasias Gástricas , Humanos , Inibidores de Checkpoint Imunológico , Fatores Imunológicos , Imunoterapia , Neoplasias Gástricas/terapia
15.
Medicine (Baltimore) ; 101(32): e29613, 2022 Aug 12.
Artigo em Inglês | MEDLINE | ID: mdl-35960045

RESUMO

INTRODUCTION: Isolated splenic metastasis emanating from colorectal cancer is an extremely rare finding, which usually indicates widely disseminated and multiple metastatic cancer. There have only been 39 cases of isolated splenic metastasis reported in the English literature to date. PATIENT CONCERNS: An 84-year-old female patient presented to our department with dark-red bloody stool that had persisted for 1 month and with an increased serum carcinoembryonic antigen (CEA) level. DIAGNOSES: A colonoscopy showed a rectal mass located 3 cm from the anal margin, which was 45 mm in diameter. The patient was diagnosed with rectal cancer with splenic metastases by abdomen computed tomography. INTERVENTIONS: The patient underwent a radical resection of rectal cancer and splenectomy, and the postoperative histopathology confirmed that the splenic lesions were derived from the adenocarcinoma of the rectum. OUTCOMES: After surgical treatment, the patient recovered well and was recommended for further chemotherapy. CONCLUSIONS: In addition to revealing a rare case, we also performed a literature review, including a brief discussion about the atypical isolated splenic metastasis from colorectal cancer. Our findings enrich the database of this rare clinical entity and provide experience in the management of splenic metastasis.


Assuntos
Adenocarcinoma , Segunda Neoplasia Primária , Neoplasias Retais , Neoplasias Esplênicas , Adenocarcinoma/patologia , Idoso de 80 Anos ou mais , Feminino , Humanos , Esplenectomia , Neoplasias Esplênicas/secundário , Neoplasias Esplênicas/cirurgia , Tomografia Computadorizada por Raios X
17.
Sci Rep ; 12(1): 13128, 2022 07 30.
Artigo em Inglês | MEDLINE | ID: mdl-35908046

RESUMO

Multiple myeloma (MM) is an incurable haematological malignancy, caused by the uncontrolled proliferation of plasma cells within the bone marrow (BM). Obesity is a known risk factor for MM, however, few studies have investigated the potential of dietary intervention to prevent MM progression. Calorie restriction (CR) is associated with many health benefits including reduced cancer incidence and progression. To investigate if CR could reduce MM progression, dietary regimes [30% CR, normal chow diet (NCD), or high fat diet (HFD)] were initiated in C57BL/6J mice. Diet-induced changes were assessed, followed by inoculation of mice with Vk*MYC MM cells (Vk14451-GFP) at 16 weeks of age. Tumour progression was monitored by serum paraprotein, and at endpoint, BM and splenic tumour burden was analysed by flow cytometry. 30% CR promoted weight loss, improved glucose tolerance, increased BM adiposity and elevated serum adiponectin compared to NCD-fed mice. Despite these metabolic changes, CR had no significant effect on serum paraprotein levels. Furthermore, endpoint analysis found that dietary changes were insufficient to affect BM tumour burden, however, HFD resulted in an average two-fold increase in splenic tumour burden. Overall, these findings suggest diet-induced BM changes may not be key drivers of MM progression in the Vk14451-GFP transplant model of myeloma.


Assuntos
Neoplasias da Medula Óssea , Mieloma Múltiplo , Doenças não Transmissíveis , Neoplasias Esplênicas , Animais , Restrição Calórica/métodos , Dieta Hiperlipídica , Camundongos , Camundongos Endogâmicos C57BL , Mieloma Múltiplo/complicações , Obesidade/metabolismo , Paraproteínas
18.
Vet Clin Pathol ; 51(3): 414-421, 2022 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-35909229

RESUMO

An 11-year-old spayed female American Cocker Spaniel was presented with a 4-week history of anorexia and a 1-week history of abdominal distension. Clinicopathologic and imaging abnormalities included intra-abdominal hemorrhage, granular lymphocytes (GLs) in abdominal fluid smears, a splenic mass, and hepatomegaly with diffuse multiple hypoechogenic nodules. Based on the cytologic, histologic, and immunohistochemical evaluation of the spleen and liver, the diagnosis was hepatosplenic T-cell lymphoma (HSTCL) of GLs. Postoperatively, the dog was maintained in good condition with chemotherapy (ACNU [nimustine], L-asparaginase, and prednisolone). However, on day 85, ultrasound-guided fine-needle aspiration of the liver revealed a proliferation in neoplastic mast cells not associated with the GLs. The dog was diagnosed with a visceral mast cell tumor (MCT) originating from the liver. The chemotherapy was switched to vinblastine and toceranib. The dog remained in good condition until day 141 but died due to the progression of MCT on day 158. Liver cytology on day 155 showed no GLs, although HSTCL is thought to be resistant to chemotherapy. After the definitive diagnosis of HSTCL, we monitored this patient's response to chemotherapy with blood tests, including complete blood counts, ultrasound imaging, and cytologic aspirates of liver. Although canine HSTCL has a poor prognosis, the possibility of a new neoplasm, including visceral MCT, should be considered. Periodic liver cytology might be worthwhile in dogs receiving chemotherapy for HSTCL.


Assuntos
Doenças do Cão , Neoplasias Hepáticas , Linfoma , Neoplasias Primárias Múltiplas , Neoplasias Esplênicas , Animais , Doenças do Cão/diagnóstico , Doenças do Cão/tratamento farmacológico , Doenças do Cão/patologia , Cães , Feminino , Neoplasias Hepáticas/diagnóstico , Neoplasias Hepáticas/tratamento farmacológico , Neoplasias Hepáticas/veterinária , Linfoma/veterinária , Mastócitos/patologia , Neoplasias Primárias Múltiplas/veterinária , Neoplasias Esplênicas/diagnóstico , Neoplasias Esplênicas/tratamento farmacológico , Neoplasias Esplênicas/veterinária
19.
PLoS One ; 17(7): e0264986, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35867969

RESUMO

Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs that is similar to human angiosarcoma (AS). HSA is a clinically, physiologically, and genomically complex canine cancer that may serve as a valuable model for understanding the origin and clinical impact of cancer heterogeneity. We conducted a prospective collection of 52 splenic masses from 43 dogs (27 HSA, 15 benign masses, and 1 stromal sarcoma) presenting for emergency care with hemoperitoneum secondary to a ruptured splenic mass. Multi-platform genomic analysis included matched tumor/normal targeted sequencing panel and exome sequencing. We found candidate somatic cancer driver mutations in 14/27 (52%) HSAs. Among recurrent candidate driver mutations, TP53 was most commonly mutated (30%) followed by PIK3CA (15%), AKT1 (11%), and CDKN2AIP (11%). We also identified significant intratumoral genomic heterogeneity, consistent with a branched evolution model, through multi-region exome sequencing of three distinct tumor regions from selected primary splenic tumors. These data provide new perspectives on the genomic landscape of this veterinary cancer and suggest a cross-species value for using HSA in pet dogs as a naturally occurring model of intratumoral heterogeneity.


Assuntos
Doenças do Cão , Hemangiossarcoma , Neoplasias Esplênicas , Animais , Doenças do Cão/genética , Cães , Genômica , Hemangiossarcoma/genética , Hemangiossarcoma/veterinária , Humanos , Mutação , Estudos Prospectivos , Neoplasias Esplênicas/genética , Neoplasias Esplênicas/veterinária
20.
Curr Oncol ; 29(6): 4117-4124, 2022 06 06.
Artigo em Inglês | MEDLINE | ID: mdl-35735437

RESUMO

Standard treatment regimens for the management of patients with refractory splenic marginal zone lymphoma (SMZL) are currently unavailable. Here, we report a case of SMZL, which, after failing multiple therapeutics, demonstrated an impressive clinical response to combined Venetoclax and Velcade (V2), a treatment combination currently being investigated in the setting of refractory multiple myeloma. We also report a unique histopathology and mutational profile that may have important implications for the characterization and prognosis of SMZL.


Assuntos
Leucemia Linfocítica Crônica de Células B , Linfoma , Neoplasias Esplênicas , Bortezomib/uso terapêutico , Compostos Bicíclicos Heterocíclicos com Pontes , Humanos , Neoplasias Esplênicas/tratamento farmacológico , Neoplasias Esplênicas/patologia , Sulfonamidas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...